Cargando…
COVID-19 and Fatty Liver Disorders
In late 2019, the world was shaken by the COVID-19 pandemic. Severe Acute Respiratory Syndrome Coronavirus—2 (SARS-CoV-2) infection became one of the main causes of illness and hospitalization worldwide, especially in subjects with metabolic comorbidities such as obesity, diabetes, or liver disease....
Autores principales: | Guarino, Maria, Cossiga, Valentina, Cutolo, Francesco Maria, Attanasio, Maria Rosaria, Lieto, Raffaele, Morisco, Filomena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342635/ https://www.ncbi.nlm.nih.gov/pubmed/37445349 http://dx.doi.org/10.3390/jcm12134316 |
Ejemplares similares
-
Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
por: Cossiga, Valentina, et al.
Publicado: (2023) -
Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022) -
Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study
por: Guarino, Maria, et al.
Publicado: (2020) -
Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023) -
Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions
por: Cossiga, Valentina, et al.
Publicado: (2023)